Dimiter V. Tassev, PhD

Executive Director (Healthcare Sector Specialist), UBS, New York, NY
Dimiter V. Tassev
Dissertation
Generation and Use of HLA-A2-Restricted, Peptide-Specific Monoclonal Antibodies and Chimeric Antigen Receptors
Mentor
Nai-Kong V. Cheung, MD, PhD
End Year
2012
Education
The Ohio State University
Publications

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O’Reilly RJ, Cheung NK. (2015) Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.  Leukemia.

Cheung N, Guo H, Hu J, Tassev D, Cheung I. (2012) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology, 1, 477-486.

Tassev D, Cheng M, Cheung N. (2011) Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther, 19, 84-100. 

Tassev D, Cheung N. (2009) Monoclonal Antibody Therapies for Solid Tumors. Expert Opin Biol Ther, 9, 341-353.

View a full listing of Dimiter V. Tassev’s journal articles.